N2913
N-TER™ Nanoparticle siRNA Transfection System
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
NACRES:
NA.51
UNSPSC Code:
12352200
form
liquid
shipped in
wet ice
storage temp.
−20°C
Application
The N-TER Nanoparticle siRNA Transfection System is a peptide-based system for use in the transient knockdown of eukaryotic gene expression. The N-TER Peptide binds siRNAs non-covalently, forming a nanoparticle. This nanoparticle interacts directly with lipids on the surface of the plasma membrane, allowing the nanoparticle to diffuse across the cell membrane and deliver the siRNA directly to the cytoplasm. Unlike most lipid-based transfection methods, this novel delivery mechanism bypasses the endosomal pathway, eliminating possible compartmentalization and degradation of the siRNA.
Legal Information
Manufactured and Distributed by Sigma-Aldrich, under license from the CNRS.
N-TER is a trademark of Sigma-Aldrich Co. LLC
Storage Class
12 - Non Combustible Liquids
wgk
nwg
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Articles
This discussion will highlight some of these methodologies, namely, the use of Multiple Reaction Monitoring (MRM) and Protein-AQUA.
Related Content
Reverse Transfection Using N-TER/siRNA Nanoparticles
N-TER/siRNA nanoparticle mediated knockdown of gene expression - HUVEC cells
Federica Simeoni et al.
Nucleic acids research, 31(11), 2717-2724 (2003-05-29)
The improvement of non-viral-based gene delivery systems is of prime importance for the future of gene and antisense therapies. We have previously described a peptide-based gene delivery system, MPG, derived from the fusion peptide domain of HIV-1 gp41 protein and
L Crombez et al.
Biochemical Society transactions, 35(Pt 1), 44-46 (2007-01-20)
The major obstacle to clinical development of siRNAs (short interfering RNAs), like for most of the nucleic-acid-based strategies, is their poor cellular uptake and bioavailability. Although several viral and non-viral strategies have been proposed to improve siRNA delivery, their applications
Sébastien Deshayes et al.
Advanced drug delivery reviews, 60(4-5), 537-547 (2007-11-27)
The recent discovery of new potent therapeutic molecules which do not reach the clinic due to poor delivery and low bioavailability have made of delivery a key stone in therapeutic development. Several technologies have been designed to improve cellular uptake